Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 297 for:    retinopathy of prematurity
Previous Study | Return to List | Next Study

A Fatty Acids Study in Preventing Retinopathy of Prematurity (DonnaMega)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02760472
Recruitment Status : Completed
First Posted : May 3, 2016
Last Update Posted : May 3, 2016
Sponsor:
Information provided by (Responsible Party):
Carola Pfeiffer-Mosesson, Queen Silvia Children's Hospital, Gothenburg, Sweden

Brief Summary:

Most fatty acids, important for development and especially the Omega-3 fatty acids for the brain development are transferred in the third trimester with means that in the premature infant this transport via the placenta is interrupted and the infant is dependent on the concentrations in breast milk which vary depending on the mother's diet and her stores. It has even been suggested that low Omega-3 would be a cause of premature delivery. Many countries have much higher levels of Omega-3 fatty acids in breast milk than found in Sweden and breast milk substitutions are generally now supplemented with the Long Chained Poly Unsaturated Fatty Acids (LCPUFA). Therefore the supplementation to be given can not be seen to give any risks for the infant. On the contrary, several studies have shown that mother who eat equal to or less than twice fish a week during pregnancy give birth to infants with impaired development.

Low Omega-3 levels in premature infants between gestational ages of 23 and 40 weeks can be one reason for Retinopathy of Prematurity (ROP) development. Restoration of Omega-3, Dokosahexaenacid (DHA) and Eikosapentaenacid (EPA) to normal in utero levels may prevent ROP by allowing normal vessel growth and survival. An increase of Omega-3 levels bringing levels to within physiological range may prevent development of ROP.


Condition or disease Intervention/treatment Phase
Retinopathy of Prematurity Drug: SMOFlipid Drug: Clinoleic Phase 3

Detailed Description:

The study is a Randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum and Breast Milk in preventing Retinopathy of Prematurity.

Subjects who meet all inclusion and none of the exclusion criteria will be enrolled into the study. Upon entry into the study, subjects will be randomized and given a unique subject number.

A randomised intervention study of 45+45 infants without major malformations born with a gestational age less than 28 weeks + 0 days will be performed.

Randomization of the patients to either:

  1. Conventional fatty acid supplementation regime with Clinoleic (with Vitalipid infant and Soluvit supplementation) to the preterm infant

    Or

  2. SMOFlipid, (soybean oil, medium chain triglycerides, olive oil and fish oil),(with Vitalipid infant and Soluvit supplementation), where the quotient of Omega 6:3 is 2.5:1 in order to mimic the physiologic relation of fatty acids in cord blood from birth, to the preterm infant.

Thus there is one group of infants (n=45) that will receive Omega-3 in the fatty acid supplementation.

The time on parenteral nutrition and the amount of fatty acids given will be according to clinical routines.

The randomization of the patients will be performed by the controller of the study. Randomization will be in blocks with 10 children in each block.

Data collection

After the investigators have received informed consent from the parents/guardians, blood samples 0.2 ml from the child will be taken according to present clinical practice at if possible from cord (2ml) and at days 0, 7, 14, 28 and in postmenstrual weeks 32, 36 and 40. Blood samples from the mothers for Fatty Acids analyses will be taken after birth, day 7 and at gestational weeks 36 and 40. At the same time (except from day 1), breast milk samples are taken. Length in cm, weight in gram and head circumference in cm are measured weekly.

Screening for ROP will be performed, at least once a week, according to clinical routines using a specific protocol.

The investigators intend to analyze the content of phospholipids which can be done on small amounts of blood, is relatively insensitive to short term fluctuations in intake and mirror the composition of many membranes in the body. The analyses will be made using gas-liquid chromatography. The method has a coefficient of variability of 1-3% for the Fatty Acids concerned.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Randomised Intervention Single Center Study to Determine the Role of Fatty Acids in Serum in Preventing Retinopathy of Prematurity
Study Start Date : March 2013
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

Drug Information available for: SMOFlipid

Arm Intervention/treatment
Active Comparator: Clinoleic
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
Drug: Clinoleic
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity

Experimental: SMOFlipid
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
Drug: SMOFlipid
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity




Primary Outcome Measures :
  1. Retinopathy of Prematurity [ Time Frame: When the retina is fully vascularised,i.e. at approximately 40 postmenstrual weeks. ]
    We intend to analyze the content of Fatty Acids and correlate to Retinopathy of Prematurity development and interventional treatment. Analyze of phospholipids can be done on small amounts of blood, is relatively insensitive to short term fluctuations in intake and mirror the composition of many membranes in the body. The analyses will be made using gas-liquid chromatography. The method has a coefficient of variability of 1-3% for the Fatty Acids concerned.


Secondary Outcome Measures :
  1. Brain Growth [ Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years. ]
    Cranial ultrasound will be performed according to clinical praxis. MRI of the brain will be performed at 40 weeks postmenstrual age (PMA) and correlated to interventional treatment.

  2. Length in cm [ Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years. ]
    Length in cm given in absolute values and in standard deviation scores, at 40 weeks postmenstrual age (PMA) and at 2.5 and 6 years will be correlated to interventional treatment.

  3. Weight in gram [ Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years. ]
    Weight in gram given in absolute values and in standard deviation scores, at 40 weeks postmenstrual age (PMA) and at 2.5 and 6 years will be correlated to interventional treatment.

  4. Head circumference in cm [ Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years. ]
    Head circumference in cm given in absolute values and in standard deviation scores, at 40 weeks postmenstrual age (PMA) and at 2.5 and 6 years will be correlated to interventional treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   23 Weeks to 28 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent from parents/guardians;
  2. Subject must be below 28 weeks of gestation

Exclusion Criteria:

  1. Detectable clinical gross malformation;
  2. Known or suspected chromosomal abnormality, genetic disorder, or syn-drome, according to the investigator's opinion;
  3. Clinically significant neuropathy, nephropathy, retinopathy, or other micro- or macrovascular disease requiring treatment, according to the investigator's opinion;
  4. Any other condition or therapy that, in the investigator's opinion, may pose a risk to the subject or interfere with the subject's ability to be compliant with this protocol or interfere with interpretation of results.
  5. Bleeding disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02760472


Sponsors and Collaborators
Carola Pfeiffer-Mosesson
Investigators
Layout table for investigator information
Principal Investigator: Carola Pfeiffer-Mosesson, RN The Queen Silvia Children's Hospital

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Carola Pfeiffer-Mosesson, Research Nurse, Queen Silvia Children's Hospital, Gothenburg, Sweden
ClinicalTrials.gov Identifier: NCT02760472     History of Changes
Other Study ID Numbers: 2008-000046-31
First Posted: May 3, 2016    Key Record Dates
Last Update Posted: May 3, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Keywords provided by Carola Pfeiffer-Mosesson, Queen Silvia Children's Hospital, Gothenburg, Sweden:
Retinopathy of Prematurity
Preterm
Fatty acids

Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Diseases
Premature Birth
Retinopathy of Prematurity
Eye Diseases
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Infant, Premature, Diseases
Infant, Newborn, Diseases